The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine

Данилов, Д. С.; Magomedova, D. O.; Matsneva, M. E.

doi:10.14412/2074-2711-2016-1-71-81

Cited by 2 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is better to consider their use in cases where the use of ADs of other pharmacological groups is impossible. Also, it is worth mentioning that the negative symptoms of schizophrenia proved to be better corrected when using selegiline, duloxetine, fluvoxamine, mirtazapine, and SSRIs [128]. Clinical trials show that the additional use of AD together with AP for the correction of depressive disorders in schizophrenia may affect the cognitive functions of patients [129,130].…”

Section: Discussionmentioning

confidence: 99%

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Novitsky

Sousa

Asadullin

et al. 2021

jour

View full text Add to dashboard Cite

The purpose of this review is to analyze approaches to the treatment of depressive and negative disorders in schizophrenia in terms of their level of efficacy and safety. Materials and Methods: A search was conducted for full-text articles published over the last 10 years in PubMed, Springer, Wiley Online Library, Taylor & Francis Online, APA PsycInfo, CORE, Science Direct, and eLIBRARY.RU databases. Several articles published previously to this period were also included into the review due to their high scientific value. Results: Our review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs). However, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance. Negative symptoms of schizophrenia, including those induced by a number of АP, are less amenable to correction by АDs monotherapy, which requires a long period of АPs (on average - 8 weeks), which can be limited in the real life of the patient outside the hospital. Current approaches to the therapy of depressive disorders in patients suffering from schizophrenia vary from country to country. However, most of АDs used in clinical psychiatric practice are widely used in the comorbid state under consideration. Conclusion: The efficacy and safety of АDs of the different classes considered in this review depends on their mechanisms of action, duration of admission, type of АPs taken, and specific clinical situation (acute depressive disorder, major depressive episode, or chronic depressive episode). Most promising in clinical practice are serotonin–norepinephrine reuptake inhibitors (SNRIs) and dual ADs. The use of tricyclic antidepressants (TCAs) is limited due to a higher risk of adverse drug reactions (ADRs). The use of most selective serotonin reuptake inhibitors (SSRIs) is limited due to the risk of aggravation of hallucinations (this risk being higher for patients with visual hallucinations, and lower for those with auditory hallucinations) and\or iatrogenic psychosis. These ADRs may probably occur in patients suffering from schizophrenia due to their ideal "poor metabolizer" pharmacogenetic profile, since most of the drugs considered in this review have hepatic metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Novitsky

Sousa

Asadullin

et al. 2021

jour

View full text Add to dashboard Cite

show abstract

Multidisciplinary and differentiated approach in the treatment of psychotic disorders with comorbid somatic states

Oprya¹,

Пустовойт²

2021

UVP

View full text Add to dashboard Cite

The article presents the results of a comprehensive clinical and psychopathological study of the features of clinical manifestations of psychotic patients with schizophrenia with somatic disorders. It has been proven that disorders in schizophrenia are associated with a negative clinical-psychopathological and socio-personal prognosis, leading to increase of severity of psychopathological symptoms and a decrease in the level of socio-psychological functioning. The identified features of the clinical course have become the leading target features, a system of multidisciplinary and differentiated approach in the complex therapy of patients taking into account somatic comorbidity has been developed and implemented in practice. The proposed system is a set of activities, including a combination of pharmacotherapeutic, psychoeducational, psychotherapeutic and psychosocial activities, selected taking into account the specifics of the psychopathological process modified by somatic pathology. According to the results of testing, its effectiveness has been proven, and it has been established that its use can significantly improve the condition of patients and their level of socio-psychological functioning, increase the stability of remission and reduce the number of hospitalizations.

show abstract

The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine

Cited by 2 publications

References 54 publications

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Multidisciplinary and differentiated approach in the treatment of psychotic disorders with comorbid somatic states

Contact Info

Product

Resources

About